Emmanuelle Charpentier is a French microbiologist, geneticist and biochemist. She received her scientific education at the University Pierre and Marie Curie and the Pasteur Institute in Paris, France.
Emmanuelle is Founding, Scientific and Managing Director of the Max Planck Unit for the Science of Pathogens and Honorary Professor at Humboldt University, Berlin, Germany. Prior to her current appointments, she held Professorship positions at the Helmholtz Centre for Infection Research and Hannover Medical School, Germany, Umeå University, Sweden and University of Vienna, Austria. She also held research associate positions at The Rockefeller University, New York University Medical Center and Skirball Institute of Biomolecular Medicine, New York, and St. Jude Children’s Research Hospital, Memphis.
Emmanuelle has been widely recognized for her groundbreaking research that laid the foundation for the revolutionary CRISPR-Cas9 genome engineering technology. She has received numerous prestigious international awards and honors including the Nobel Prize in Chemistry in 2020, and is an elected member of national and international scientific academies. She is co-founder of CRISPR Therapeutics and ERS Genomics with Rodger Novak and Shaun Foy.
More information about Emmanuelle is available at www.emmanuelle-charpentier.org.
Professional position
- Scientific and Managing Director, Max Planck Unit for the Science of Pathogens, Max Planck Society
Subject groups
-
Molecules of Life
Biochemistry and molecular biology, Molecular microbiology
-
Cell Biology
General microbiology (incl bacteriology and virology), Genetics (excluding population genetics)
-
Health and Human Sciences
Medical microbiology
Awards
-
Nobel Prize in Chemistry
For the development of a method for genome editing
